Anavex Life Sciences Revenue
Biotechnology Research • 
Manhattan, New York, United States • 21-50 Employees
Anavex Life Sciences revenue & valuation
| Annual revenue | $11,000,000 |
| Revenue per employee | $254,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $35,000,000 |
| Total funding | $200,000,000 |
Key Contacts at Anavex Life Sciences
Kim Tharaldsen
Executive Director, Medical Affairs & Advocacy
Janusz Debowski
Director Analytical Development
Ashley Seragusa
Associate Director, Clinical Data Management
Yanning Liu
Senior Director
Mireilly Figueroa
Executive Director, Clinical Data Management
Biman Pal
Director, Drug Substance, Cmc
Trupti P
Associate Director Of Clinical Operations
James Tran
Associate Director Of Clinical Research
Edison Guamba
Associate Director Of Clinical Operations
Sandro Javier
Director Of Business Development
Company overview
| Headquarters | Manhattan, New York, United States |
| Phone number | +120072025 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Employees | 21-50 |
| Socials |
Anavex Life Sciences Email Formats
Anavex Life Sciences uses 1 email format. The most common is {first name}{last name} (e.g., johndoe@anavexcorp.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@anavexcorp.com | 100% |
About Anavex Life Sciences
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Anavex Life Sciences has 21 employees across 7 departments.
Departments
Number of employees
Funding Data
Explore Anavex Life Sciences's funding history, including investment rounds, total capital raised, and key backers.
Anavex Life Sciences Tech Stack
Discover the technologies and tools that power Anavex Life Sciences's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Issue trackers
Appointment scheduling
Tag managers
Blogs
Miscellaneous
Security
Miscellaneous
JavaScript frameworks
JavaScript frameworks
JavaScript frameworks
IaaS
Dominican Republic
Spain
Afghanistan
NigeriaFrequently asked questions
4.8
40,000 users
